Stoke Therapeutics (NASDAQ:STOK) Releases Quarterly Earnings Results, Beats Expectations By $0.38 EPS

Stoke Therapeutics (NASDAQ:STOK) released its quarterly earnings data on Tuesday. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.38, Zacks reports. The firm had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK opened at $8.69 on Wednesday. The company has a market capitalization of $460.28 million, a PE ratio of -4.14 and a beta of 0.99. The business has a fifty day moving average price of $9.52 and a two-hundred day moving average price of $11.54. Stoke Therapeutics has a 1 year low of $5.60 and a 1 year high of $17.58.

Analyst Upgrades and Downgrades

STOK has been the subject of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Chardan Capital reiterated a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $47.00 price target on shares of Stoke Therapeutics in a report on Wednesday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Stoke Therapeutics currently has a consensus rating of “Buy” and an average price target of $23.00.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.